uniQure Stock Drops Despite FDA Priority Review for Huntington's Gene Therapy
uniQure's stock fell 3% despite receiving FDA priority review for its Huntington's disease gene therapy AMT-130.
uniQure's stock fell 3% despite receiving FDA priority review for its Huntington's disease gene therapy AMT-130. This is an original Token Times brief based on reporting by Blockonomi, with live market data added, as of Mon, 02 Nov 2026 19:45:02 UTC.
The FDA's priority review designation for AMT-130 highlights the potential of gene therapy in treating Huntington's disease, a devastating neurodegenerative condition with no current cure. This regulatory milestone could accelerate the therapy's path to market and impact the broader gene therapy landscape.
- FDA grants priority review to uniQure's Huntington's gene therapy AMT-130.
- Decision expected by May 1, 2027.
- uniQure plans to start screening 200 patients for confirmatory trial by year-end.
- QURE stock fell 3% despite the positive regulatory news.
uniQure's stock experienced a 3% decline, falling to $24.09, despite receiving FDA priority review for its gene therapy AMT-130 targeting Huntington's disease. The FDA has set a target decision date of May 1, 2027, for the therapy, which uses uniQure's proprietary gene-silencing platform.
The company plans to initiate screening for a confirmatory trial involving 200 patients by the end of 2023. This development marks a significant step in the treatment of Huntington's disease, a genetic disorder with no current cure.
The news of the FDA's priority review, typically reserved for therapies that offer significant improvements over existing treatments, was not enough to prevent a drop in uniQure's stock. This suggests that investors may be cautious about the therapy's potential market impact or the competitive landscape.
In broader market news, Rivian's stock rose over 3% after UBS upgraded the company to a Buy rating with a $17 price target, citing stronger sales, demand for the R2 model, and improving profit margins. This contrasts with the downward trend in the overall market, which saw a 1.07% decline in 
Bitcoin and a total crypto market cap of $2.65 trillion.
The market's Fear & Greed index currently stands at 37, indicating a 'Fear' sentiment. This suggests that investors are cautious amidst broader economic uncertainties, which may have contributed to the negative market reaction to uniQure's news.
1 key figure independently matched across 2 outlets reporting this story.
Token Times extracts the figures each outlet reports and flags the ones that agree. Numbers cited by only one outlet are attributed in the brief, not shown as corroborated.
uniQure Stock Drops Despite FDA Priority Review for Huntingt — questions & answers
What is the FDA's decision date for AMT-130?
The FDA plans to make a decision on AMT-130 by May 1, 2027.
How many patients will be screened for the confirmatory trial?
uniQure plans to screen 200 patients for the confirmatory trial by year-end.
Why did uniQure's stock fall despite the positive news?
The stock may have fallen due to investor caution about the therapy's market potential or broader market conditions.
Which outlets reported this story?
This is an original Token Times brief that synthesises reporting from Blockonomi. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original Token Times brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.